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IMPORTANCE More than 70% of patients with resistant hypertension have obstructive sleep
apnea (OSA). However, there is little evidence about the effect of continuous positive airway
pressure (CPAP) treatment on blood pressure in patients with resistant hypertension.
OBJECTIVE To assess the effect of CPAP treatment on blood pressure values and nocturnal
blood pressure patterns in patients with resistant hypertension and OSA.
DESIGN, SETTING, AND PARTICIPANTS Open-label, randomized,multicenter clinical trial of
parallel groups with blinded end point design conducted in 24 teaching hospitals in Spain
involving 194 patients with resistant hypertension and an apnea-hypopnea index (AHI) of 15
or higher. Data were collected from June 2009 to October 2011.
INTERVENTIONS CPAP or no therapy while maintaining usual blood pressure control
medication.
MAIN OUTCOMES ANDMEASURES The primary end point was the change in 24-hourmean
blood pressure after 12 weeks. Secondary end points included changes in other blood
pressure values and changes in nocturnal blood pressure patterns. Both intention-to-treat
(ITT) and per-protocol analyses were performed.
RESULTS A total of 194 patients were randomly assigned to receive CPAP (n = 98) or no CPAP
(control; n = 96). Themean AHI was 40.4 (SD, 18.9) and an average of 3.8 antihypertensive
drugs were taken per patient. Baseline 24-hour mean blood pressure was 103.4mmHg;
systolic blood pressure (SBP), 144.2 mmHg; and diastolic blood pressure (DBP), 83mmHg.
At baseline, 25.8% of patients displayed a dipper pattern (a decrease of at least 10% in the
average nighttime blood pressure compared with the average daytime blood pressure). The
percentage of patients using CPAP for 4 or more hours per day was 72.4%.When the changes
in blood pressure over the study period were compared between groups by ITT, the CPAP
group achieved a greater decrease in 24-hour mean blood pressure (3.1 mmHg [95% CI, 0.6
to 5.6]; P = .02) and 24-hour DBP (3.2 mmHg [95% CI, 1.0 to 5.4]; P = .005), but not in
24-hour SBP (3.1 mmHg [95% CI, −0.6 to 6.7]; P = .10) compared with the control group.
Moreover, the percentage of patients displaying a nocturnal blood pressure dipper pattern at
the 12-week follow-up was greater in the CPAP group than in the control group (35.9% vs
21.6%; adjusted odds ratio [OR], 2.4 [95% CI, 1.2 to 5.1]; P = .02). There was a significant
positive correlation between hours of CPAP use and the decrease in 24-hour mean blood
pressure (r = 0.29, P = .006), SBP (r = 0.25; P = .02), and DBP (r = 0.30, P = .005).
CONCLUSIONS AND RELEVANCE Among patients with OSA and resistant hypertension, CPAP
treatment for 12 weeks compared with control resulted in a decrease in 24-hour mean and
diastolic blood pressure and an improvement in the nocturnal blood pressure pattern. Further
research is warranted to assess longer-term health outcomes.
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S ystemic hypertension is one of the most treatable car-diovascular risk factors.1 Between 12%and27%ofall hy-pertensive patients require at least 3 antihypertensive
drugs for adequate bloodpressure control and are considered
patients with resistant hypertension.2-4 Patients with resis-
tant hypertension are almost 50%more likely to experience a
cardiovascular event than hypertensive patients without re-
sistant hypertension, and the incidenceof resistant hyperten-
sion is expected to increase.5
Obstructive sleepapnea (OSA) affects 4%to6%of thegen-
eral middle-aged population6,7 and increases with age.8 It is
characterizedby the repeatedcollapseof theupperairwaydur-
ing the night, causing intermittent hypoxemia and sleep dis-
ruption,which in turn are
associated with an in-
creased risk for neurocog-
nitive and cardiovascular
morbidities.9Recent stud-
ies have shown that OSA
may contribute to poor
controlofbloodpressure10
and that a very high per-
centage (>70%) of resis-
tant hypertension patients have OSA.11 Accordingly, interna-
tional guidelines now recognize OSA as one of the most
common risk factors of resistant hypertension.4
Continuous positive airway pressure (CPAP) is the treat-
ment of choice for severe or symptomatic OSA.12 A meta-
analysis suggests that CPAP treatment reduces blood pres-
sure levels toaclinicallymeaningfuldegree,13 butwhether this
positive effect is more pronounced in patients with resistant
hypertension isunclearbecausestudieson this issueare scarce
and based on single-center approaches.14-16 The objective of
our study was to conduct a randomized, multicenter clinical
trial to assess the effect of CPAP treatment on blood pressure
values andnocturnal bloodpressure patterns of patientswith
resistant hypertension and OSA.
Methods
Study Design
This studywas approvedby the ethics committee of eachpar-
ticipatingcenter.All theparticipantsprovided informedsigned
consent to participate in the study. Our study was an open-
label, randomized,multicenter clinical trial of parallel groups
with ablindedendpointdesign conducted in 24 teachinghos-
pitals in Spain in patients diagnosedwith resistant hyperten-
sionandOSA.Patientswere randomlyassigned toeitherCPAP
or no therapy (control) and maintained their usual, unmodi-
fied blood pressure control medication.
Selection of Patients
Patients were consecutively recruited from the Hypertension
Clinical Units of the participating centers. Patients were ini-
tially eligible for participation in the study if they had pri-
mary resistant hypertension, were aged 18 to 75 years, and
signed the informed consent to participate. All the major
causes of resistant hypertension were ruled out in each
Hypertension Clinical Unit including primary aldosteronism,
renal artery stenosis, and renal insufficiency. Initial exclusion
criteria also included pregnancy, disabling hypersomnia
requiring urgent treatment (defined as an Epworth Sleepiness
Scale [ESS] ≥18), current use of CPAP treatment, poor adher-
ence with antihypertensive treatment, long-term treatment
with oral corticosteroids or nonsteroidal anti-inflammatory
drugs, renal insufficiency (creatinine concentration higher
than 1.5 mg/dL [to convert to micromoles per liter, multiply
by 88.4] in peripheral blood sample), a cardiovascular event
in themonth prior to the inclusion in the study, and the regu-
lar use of sedative drugs such as benzodiazepines, major opi-
ates, and antipsychotics, which could significantly modify
the results of sleep studies and alcohol intake (more than 100
grams of alcohol per day).
Procedures
Initial Visit
At the initial visit, all the patients completed a standardized
protocol that included general and anthropometric data, his-
toryof cardiovasculardiseases, currentmedications, andclini-
cal history related to OSA. The ESS was used to quantify day-
time somnolence. Good adherence to the antihypertensive
treatmentwas verified bymeans of theHaynes-Sackett test.17
This test is amethod for assessing self-reportedadherence.Pa-
tientswere also asked to bring the empty blister packs of their
antihypertensive pills to check the number of tablets missed
permonth.Goodadherencewas considered tooccurwhen the
percentage of doses takenwas between 80% and 120% of the
prescribed dose (some patients took more than the pre-
scribed dose).
Sleep Studies
All the included patients underwent attended respiratory
polygraphy18 in the sleep laboratory of each center. Respira-
torypolygraphyincludedcontinuousrecordingoforonasal flow
and pressure, heart rate, thoracic and abdominal respiratory
movements, and oxygen saturation (SaO2). Polygraphy data
were scored manually by trained personnel. Apnea was de-
fined as an interruption of oronasal airflow for more than 10
seconds.Hypopneawasdefined as a 30% to90% reduction in
oronasal airflow formore than 10 seconds, associatedwith an
oxygen desaturation of 4% or higher. Apnea-hypopnea index
(AHI)wasdefinedas thenumberof apneasplushypopneasper
hour of recording, and TSat90 was defined as the percentage
of recording timewithSaO2 less than90%.Those tests inwhich
thepatients claimedtosleep less than4hoursor inwhich there
were less than 5 hours of nocturnal recording were repeated.
Central sleep apneawas defined as at least 50%of respiratory
events having a pattern of apnea or hypopnea without respi-
ratory effort.
24-Hour Ambulatory Blood PressureMonitoring
All patients with an AHI of 15 or higher underwent an initial
24-hour ABPMmeasurement to ascertain the presence of re-
sistant hypertension and its control in accordance with stan-
dard recommendations.19,20
AHI apnea-hypopnea index
ABPM ambulatory blood pressure
monitor
CPAP continuous positive airway
pressure
DBP diastolic blood pressure
OSA obstructive sleep apnea
SBP systolic blood pressure
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The summary values in the ABPM report of each patient
in thedata analysiswereused.Data related to theaverageday-
time and nighttime systolic blood pressure (SBP), diastolic
bloodpressure (DBP), andmeanbloodpressure (definedas [⅔
DBP value] + [⅓ SBP value])21; types of nocturnal blood pres-
sure patterns (according to the increase [riser], decrease [dip-
per], or absence of a difference [nondipper] of at least 10% in
the value of the averagenighttimebloodpressure levels com-
paredto theaveragedaytime levels);20variabilityofbloodpres-
sure (defined as the standard deviation of the 24-hour mean
bloodpressure);heart rate;andbothSBPandDBP24-hourpeak
and valley values (defined as themaximum [peak] andmini-
mum [valley] 24-hour blood pressure values) were recorded.
Bloodpressure levelsweremeasuredevery20minutes inboth
the daytime and nighttime periods.
The sleeping and awaking periods were determined by
instructing the patients to record the approximate times
when they fell asleep and woke up. The 24-hour ABPM cri-
teria used to define resistant hypertension were blood pres-
sure that remained above goal (ie, average SBP ≥130 mm Hg,
average DBP ≥80 mm Hg, or both) in spite of concurrent use
of at least 3 antihypertensive medication agents prescribed
at doses that provide optimal benefit—1 of them being, ide-
ally, a diuretic, if no contraindication exists.4 Patients not
fulfilling resistant hypertension criteria were excluded from
the study.
Main OutcomeMeasures
The primary end point was the change in the 24-hour ambu-
latorymeanbloodpressure frombaseline to 12weeks of CPAP
or control. Secondary end points included changes in other
bloodpressurevalues, especiallydiurnal andnoctunalSBPand
DBP, and changes in nocturnal blood pressure patterns.
RandomAllocation
Patients with an AHI of 15 or higher in whom resistant hyper-
tension was confirmed were eligible for randomization. The
clinician responsibleuseda specific softwaredesigned for this
study (Random function of JavaScript math package) to de-
termine the group allocation for patients. Random allocation
stratified by site was used without any other restriction. The
software only revealed the allocation group when an investi-
gator provided the data of a fully eligible patient, which guar-
anteed the concealment of the randomization sequence.
CPAP Pressure Titration
For those patients randomized to CPAP treatment, optimal
CPAP pressure was titrated in the sleep laboratory on a sec-
ond night by an auto CPAP device (REMstar Pro M Series with
C-Flex, Philips Respironics) within a period of less than 15
days after the diagnostic study to obtain a fixed CPAP pres-
sure value, according to a previous validation by the Spanish
Sleep Network.22 The optimal pressure was determined by 2
blinded expert researchers, based on the visual evaluation of
the raw data recording from the night study, with no signifi-
cant leaks (less than 0.40 L/s). This fixed pressure was then
maintained throughout the study in those patients assigned
to the CPAP group.
Follow-up
Treatment with CPAP was continued for 3 months, during
which the patient had direct contact with the research team
at all times for clinical problem-solving issues. Medical ap-
pointments were scheduled for all patients (with or without
CPAP) 2weeks after randomization and, subsequently, at 4, 8,
and 12 weeks. We considered adherence as adequate if the
mean CPAP use was at least 4 hours per night. Everymedical
appointment involvedprotocol-based assessments of the fol-
lowing: adherence to CPAP and antihypertensive treatment,
appearanceofanynoteworthynewmedical circumstances (es-
pecially changes in treatments, clinical or anthropometricvari-
ables, or new vascular events), and reevaluation of the exclu-
sion criteria. At the last medical appointment, after 12 weeks
of treatment, a repeat 24-hourABPMtestwas conducted in all
patients. The CPAP device used was able to store all the data
from the 3 months of use and record the residual AHI, leaks,
and other information for each night for analysis using spe-
cific software (EncorePro, PhilipsRespironics). Datawere col-
lected from June 2009 to October 2011.
Statistical Analysis
Continuous variables were expressed as mean (SD), while
categorical variables were reported as absolute numbers
and percentages. The normality of the distribution of vari-
ables was tested using the Kolmogorov-Smirnov test. Calcu-
lation of the sample size aimed to detect a reduction of 4
mm Hg or more in 24-hour mean blood pressure, assuming
a pooled standard deviation of 8.7,23 an α error of 5%, and a
statistical power of 80%, with a total of 70 patients needed
per randomized treatment group, including both an
intention-to-treat (ITT) analysis (analyzed data from all ran-
domized patients) and a per-protocol analysis (analyzed
data only from patients with adequate adherence to CPAP
who finished the study).
The intragroup differences from the beginning to the
end of the study were evaluated with a paired t test. Inter-
group comparisons of the change in blood pressure were
assessed by analysis of covariance (ANCOVA) to adjust for
baseline blood pressure values. The hospital of inclusion
and all the clinically relevant cardiovascular risk factors that
differed significantly at baseline were also included as
covariates. The validity of the models was assessed by the
coefficient of determination R2. Also, graphical examination
was performed in order to confirm the assumptions of lin-
earity and normality of the residuals. The χ2 test was used to
compare dichotomous variables. Multiple imputation tech-
niques were used to estimate values for those patients with-
out valid measurements of blood pressure after the 12-week
follow-up. The multiple imputation method is implemented
under the assumption that the missing data are missing at
random. For the 20 patients with missing follow-up blood
pressure measurements, imputed values of these measure-
ments were generated on the basis of baseline blood pres-
sure values, sex, age, AHI, ESS, and number of initial antihy-
pertensive drugs. This was generated using multiple
imputation by chained equations, the ice command in Stata
(StataCorp), version 11.
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Logistic regression analysiswasused to estimate theodds
ratio (OR) of having adipper or riser pattern in theCPAPgroup
compared with the control group. Baseline status was in-
cluded as a covariate. Appropriate 95% CIs were also calcu-
lated. A 2-sided P value less than .05 was considered signifi-
cant. Data management and statistical analyses were
performedusing Stata, version 11, andSPSSpredictive analyt-
ics software (IBM), version 21.
Results
Of the initial 266 recruited patients, 194 were randomized,
98 to the CPAP group and 96 to the control group (ITT popu-
lation), and 174 (87 CPAP, 87 control) of these completed
the study and had valid 24-hour ABPM measurements
(Figure 1). Of the 194 randomized patients, 133 patients
(68.6%) were men. The mean (SD) for age was 56.0 (9.5)
years; body mass index (BMI; calculated as weight in kilo-
grams divided by height in meters squared), 34.1 (5.4); AHI,
40.4 (18.9) events per hour (96.1% of events were obstruc-
tive); and antihypertensive drugs taken per patient, 3.8
(0.9). Patients showing an AHI of 30 or higher were 63.9%;
an ESS of 10 or higher, 43.2%. The mean ESS was 9.1 (SD, 3.7;
range, 1-18). No patient had central sleep apnea. The mean
(SD) for baseline 24-hour mean blood pressure was 103.4
(9.6) mm Hg; SBP, 144.2 (12.5) mm Hg; and DBP, 83.0 (10.5)
mm Hg. Patients with a nondipper blood pressure nocturnal
pattern were 42.8%; riser, 31.4% (Table 1). Ten patients were
not taking a diuretic as antihypertensive treatment because
of adverse effects. The use of antihypertensive medication
is detailed in Table 2. Patients who did not complete the
follow-up were similar to those who completed it, except
that they took slightly more antihypertensive medication at
baseline (4.3 incomplete study vs 3.7 completed study;
P = .02).
The average use of CPAP treatment was 5 (1.9) hours per
night,with71patients (72.4%)using it at least4hourspernight.
The mean CPAP pressure used was 8.5 (2.1) mm Hg. The re-
sidual AHI following the application of CPAP during the titra-
tion study was 4.1 (3.8) mmHg.
Intention-to-Treat Analysis
For the ITT analysis, imputed values for blood pressure
measurements were calculated for the 20 patients with
missing follow-up blood pressure measurements due to fail-
ure to complete the protocol or an invalid 24-hour ABPM
study. When the changes in blood pressure during the study
period were compared between study groups by ITT (98
patients in the CPAP group; control group, 96 patients), the
CPAP group achieved a greater decrease in 24-hour mean
blood pressure (3.1 mm Hg [95% CI, 0.6 to 5.6]; P = .02) and
24-hour DBP (3.2 mm Hg [95% CI, 1.0 to 5.4]; P = .005), but
not 24-hour SBP (3.1 mm Hg [95% CI, −0.6 to 6.7]; P = .10)
compared to the control group (Table 3). The differences
appeared greater for nocturnal blood pressure than for day-
time blood pressure, although the 95% CIs for changes in
nocturnal and daytime blood pressure overlapped. The
model did not change when it was adjusted for potential
confounders (baseline blood pressure, AHI, ESS, nocturnal
blood pressure pattern, and previous cardiovascular events)
except for the statistically significant reduction observed in
SBP values not seen in the unadjusted model (Table 3).
Regarding nocturnal patterns, the percentage of patients
displaying a nocturnal blood pressure dipper pattern at the
12-week follow-up was greater in the CPAP group than
in the control group (35.9% CPAP vs 21.6% control; adjusted
OR, 2.4 [95% CI, 1.2 to 5.1]; P = .02). (Table 4). Also, fewer
patients in the CPAP group displayed a nocturnal riser pat-
tern at the end of the study compared to the control
group (adjusted OR, 0.45 [95% CI, 0.23 to 0.91]; P = .03)
(Table 4).
There were no differences in the percentage of patients
reaching anormotensive range in theABPM (<130/80mmHg)
between the CPAP group and control group at the end of the
study (18.4% CPAP vs 13.8% control; P = .41).
Analysis According to CPAP Tolerance
(Per-Protocol Analysis)
In a per-protocol analysis (71 patients in the CPAP group;
control group, 87 patients), patients in the CPAP group
showed a statistically significant decrease in 24-hour mean
blood pressure of 4.4 mm Hg (95% CI, 1.8-7), P = .001; SBP,
4.9 mm Hg (95% CI, 1.2-8.6), P = .01; and DBP, 4.1 mm Hg
(95% CI, 1.9-6.4), P < .001. This difference was more evident
during the night, with a decrease of 7.1 mm Hg (P = .003) in
nocturnal SBP and 4.1 mm Hg (P = .003) in nocturnal DBP.
Moreover, the proportion of patients who had a dipper pat-
tern at the end of follow-up was greater in the CPAP group
Figure 1. Flowchart of the Study
266 Patients assessed for eligibility
72 Excluded
39 Normal ABPM values
24 AHI <15
2 Refused to participate
2 Unable to contact
5 Missing AHI
194 Randomized
98 Included in intent-to-treat analysis
11 Missing data imputed
96 Included in intent-to-treat analysis
9 Missing data imputed
98 Randomized to receive CPAP
98 Received CPAP as randomized
96 Randomized to receive no therapy
96 Received no therapy as
randomized
1 Lost to follow-up
9 Discontinued intervention
7 Refused to continue
2 Changed antihypertensive
treatment
3 Lost to follow-up
4 Discontinued intervention
2 Refused to continue
2 Changed antihypertensive
treatment
87 Completed follow-up
1 Invalid final 24-hour ABPM
87 Completed follow-up
2 Invalid final 24-hour ABPM
ABPM indicates ambulatory blood pressure monitor; AHI, apnea-hypopnea
index; and CPAP, continuous positive airway pressure.
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(OR, 2.8 [95% CI, 1.3-6.3]; P = .01). Also, fewer patients in the
CPAP group displayed a nocturnal riser pattern at the end of
the study compared to the control group (OR, 0.43 [95%
CI, 0.20-0.91]; P = .03).
Figure 2 shows a positive linear correlation between the
numberofhoursofCPAPuseandthedecrease in24-hourmean
bloodpressure (r = 0.29,P = .006); SBP, (r = 0.25;P = .02); and
DBP, ; (r = 0.30,P = .005). Linear regression analysis shows an
improvement of blood pressure figures of 1.3mmHg (95%CI,
0.4 to 2.2) for mean blood pressure; SBP, 1.9 mmHg (95% CI,
0.6 to 3.3); andDBP, 1.0mmHg (95%CI, 0.1 to 1.8) for each ad-
ditional hour of CPAP use.
Discussion
There is clinical evidence thatOSA is a risk factor for thedevel-
opment and poor control of systemic hypertension.10,24,25
Nevertheless, great variabilityhas beenobservedwith respect
to the effect of treatment with CPAP on blood pressure, prob-
ably on account of the multifactorial nature of systemic
hypertension.5-22,24-29 This has led to an increasing interest in
theanalysisof subgroupsofpatientswhocouldpotentiallyben-
efit fromtheCPAPtreatment.Obstructive sleepapnea ishighly
prevalent inpatientswith resistanthypertension, regardlessof
Table 1. Baseline Characteristics of All Randomized Patients
Mean (SD)
All Patients Control Group CPAP Group
Patients, No. 194 96 98
Age, y 56.0 (9.5) 58.2 (9.6) 57.8 (9.5)
Men, No. (%) 133 (68.6) 62 (64.6) 71 (72.4)
BMI 34.1 (5.4) 33.6 (6.9) 34.3 (5.7)
≥30, No. (%) 113 (79.6) 52 (76.4) 61 (82.4)
Neck circumference, cm 42.2 (4.9) 41.5 (4.7) 42.9 (5.1)
Epworth Sleepiness Scale 9.1 (3.7) 9.3 (4.0) 8.9 (4.0)
≥10, No. (%) 76 (43.2) 43 (47.3) 33 (38.9)
Years since diagnosis of
resistant hypertension
12.8 (8.6) 13.1 (8.0) 12.5 (9.2)
No. of systemic hyperten-
sion drugs
3.8 (0.9) 3.9 (0.9) 3.7 (0.9)
Past cardiovascular events,
No. (%)
42 (21.4) 24 (25) 18 (18)
Apnea-hypopnea index,
event/h
40.4 (18.9) 39.5 (19.2) 41.3 (18.7)
≥30, No. (%) 124 (63.9) 56 (58.3) 68 (69.4)
TSat90, median (IQR) 9 (2-20) 8 (2-19) 9.5 (4-22)
Mean O2 saturation, % 92.0 (3.8) 92.0 (4.8) 91.9 (2.5)
24-h mean blood pressure,
mm Hg
103.4 (9.6) 102.9 (9.6) 103.9 (9.6)
24-h SBP, mm Hg 144.2 (12.5) 143.5 (13.2) 144.9 (11.7)
Diurnal 146.1 (12.7) 145.1 (13.3) 147.2 (12.1)
Nocturnal 140.8 (16.3) 140.4 (16.8) 141.2 (15.8)
24-h DBP, mm Hg 83.0 (10.5) 82.6 (10.0) 83.4 (11.1)
Diurnal 85.2 (11.0) 84.6 (10.4) 85.7 (11.6)
Nocturnal 78.6 (11.7) 78.6 (11.1) 78.5 (12.4)
Nocturnal blood pressure
pattern, No. (%)
Dipper 50 (25.8) 25 (26.0) 25 (25.5)
Nondipper 83 (42.8) 37 (38.5) 46 (46.9)
Riser 61 (31.4) 34 (35.4) 27 (27.6)
Variability, mm Hg 11.7 (3.1) 11.6 (3.5) 11.7 (3.6)
Heart rate, beats/min 71.8 (11.3) 73.3 (11.1) 70.3 (11.7)
Valley blood pressure,
mm Hg
24-h SBP 111.5 (14.7) 111.0 (14.3) 111.9 (15.4)
24-h DBP 64.2 (12.2) 60.3 (11) 59.6 (11.6)
Peak blood pressure,
mm Hg
24-h SBP 160.9 (17.7) 160.2 (17.3) 161.8 (18)
24-h DBP 93.5 (13.1) 92.8 (12.4) 93.9 (13.7)
Abbreviations: BMI, bodymass index
(calculated as weight in kilograms
divided by height in meters squared);
CPAP, continuous positive airway
pressure; DBP, diastolic blood
pressure; IQR, interquartile range;
SBP, systolic blood pressure; TSat90,
nighttime spent with an oxygen
saturation below 90%.
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otherconfoundingvariablessuchasthepresenceofobesity,11,30,31
thus suggesting this subgroupofhypertensivepatients is apo-
tential worthwhile population for CPAP treatment.
Internationalguidelineshavepointedoutthatevenminimal
reductions in the blood pressure levels (to the order of 2-3mm
HgofSBP)couldhaveaclinically significanteffectbygreatly re-
ducing subsequent cardiovascularmortality (between 6%-8%
forstrokeand4%-5%forcoronaryheartdisease).32Veryfewstud-
ieshaveassessedtherole forCPAPtreatment inpatientswithre-
sistanthypertensionandOSA.Theavailablestudieshave found
clinically significant reductions in blood pressure levels, espe-
ciallyduring thenightandparticularly inpatientswithgoodad-
herencetoCPAPtreatment.However,allof thesestudieshadsig-
nificantmethodological limitations(eg, lackofrandomization14,15
and small cohorts)14-16 leading their authors to emphasize the
needfor furtherstudieswithrigorousstudydesigns. In linewith
thepublishedevidence,our results confirmthat there is a clini-
callyandstatisticallysignificantreductioninboth24-hourmean
anddiastolic bloodpressure levels, especially during thenight
and in those patientswith acceptable CPAP adherence.
Table 3. Effect of Continuous Positive Airway Pressure Treatment on Blood Pressure Levels in the Intention-to-Treat Population
Mean (SD)
Intergroup
Crudea
Differences
(95% CI)
P
Value
Intergroup
Adjustedb
Differences
(95% CI)
P
Value
CPAP Group
(n = 98)
Control Group
(n = 96)
Baseline Follow-up Baseline Follow-up
BP variables,
mm Hgc
24-h mean BP 103.9 (9.6) 99.8 (14.6) 102.9 (9.6) 102.1 (18.2) 3.1 (0.6 to 5.6) .02 3.9 (1.3 to 6.6) .004
24-h SBP 144.9 (11.7) 140.2 (13.1) 143.5 (13.2) 142.3 (17.1) 3.1 (−0.6 to 6.7) .10 4.2 (0.4 to 8.0) .03
Diurnal 147.2 (12.1) 144.0 (13.7) 145.1 (13.3) 142.5 (16.2) −0.3 (−4.0 to 3.5) .89 1.1 (−2.9 to 5.2) .59
Nocturnal 141.2 (15.8) 134.6 (16.4) 140.4 (16.8) 137.8 (19.4) 3.7 (−0.8 to 8.2) .11 5.8 (1.1 to 10.5) .02
24-h DBP 83.4 (11.1) 79.5 (11.5) 82.6 (10.0) 82.1 (12.7) 3.2 (1.0 to 5.4) .005 3.8 (1.4 to 6.1) .002
Diurnal 85.7 (11.6) 82.7 (12.5) 84.6 (10.4) 83.2 (13.2) 1.5 (−0.8 to 3.9) .20 2.3 (−0.1 to 4.8) .07
Nocturnal 78.5 (12.4) 75.4 (11.7) 78.6 (11.1) 77.5 (13.5) 2.1 (−0.6 to 4.7) .13 3.3 (0.5 to 6.1) .02
Valley BP
24-h SBP 111.9 (15.4) 106.2 (17.8) 111.0 (14.3) 103.3 (20.2) −2.6 (−7.9 to 2.6) .32 −0.4 (−6.0 to 5.3) .90
24-h DBP 59.6 (11.6) 57.4 (11.1) 60.3 (11.0) 58.4 (13.1) 0.5 (−2.3 to 3.3) .71 2.2 (−0.7 to 5.1) .14
Peak BP
24-h SBP 161.8 (18.0) 150.5 (25.1) 160.2 (17.3) 149.6 (28.9) −0.3 (−8.0 to 7.4) .93 0.5 (−7.5 to 8.6) .89
24-h DBP 93.9 (13.7) 88.4 (14.2) 92.8 (12.4) 92.8 (14.0) 5.0 (1.8 to 8.3) .003 5.7 (2.3 to 9.2) .001
BMI 34.3 (5.7) 34.5 (5.2) 33.6 (6.9) 33.6 (6.0) −0.4 (−1.8 to 1.0) .54 0.1 (−0.4 to 0.7) .64
ESS 8.9 (4.0) 5.5 (4.1) 9.3 (4.0) 9.0 (4.5) 3.3 (2.3 to 4.2) <.001 3.4 (2.4 to 4.3) <.001
Heart rate,
beats/min
70.3 (11.7) 70.1 (14.8) 73.3 (11.1) 73.0 (11.7) 0.9 (−2.3 to 4.0) .59 0.6 (−2.8 to 3.9) .74
Variability 11.7 (3.6) 11.9 (4.4) 11.6 (3.5) 12.6 (4.3) 0.8 (−0.5 to 2.0) .24 0.4 (−0.8 to 1.6) .52
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared); BP, blood pressure; CPAP, continuous positive
airway pressure; DBP, diastolic blood pressure; ESS, Epworth Sleepiness Scale;
SBP, systolic blood pressure.
a Adjusted by baseline BP values.
bAdjusted by baseline BP, AHI, ESS, dipper or riser status, and previous
cardiovascular events.
c Crude differences calculated as (change in CPAP group) − (change in control
group).
Table 2. Use of Prescribed AntihypertensiveMedication in Randomized Patients
No. (%)
All Patients
Treatment
Control Group CPAP Group
Patients, No. 194 96 98
Diuretica 184 (94.8) 89 (93.7) 95 (96.9)
Calcium channel blockers 142 (72.4) 69 (71.9) 73 (73)
Angiotensin II receptor
blockers
132 (67.3) 64 (66.7) 68 (68)
β-Blockers 112 (57.1) 54 (56.3) 58 (58)
Angiotensin-converting
enzyme inhibitor
75 (38.3) 38 (39.6) 37 (37)
α1-Blockers 65 (33.1) 32 (33.3) 33 (33)
Renin blockers 21 (10.7) 8 (8.3) 13 (13)
Others 8 (4.1) 4 (4.2) 4 (4)
Abbreviation: CPAP, continuous
positive airway pressure.
a Ten patients were not taking
diuretic treatment due to adverse
effects.
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The recovery of the dipper nocturnal pattern with antihy-
pertensive treatment may be advantageous because the pres-
enceofnondipperor riserbloodpressurenocturnalpatternshas
emerged as an independent cardiovascular risk factor. In our
study,more than 70%of patients had a nondipper or riser pat-
tern and CPAP treatment normalized the blood pressure noc-
turnalpatterninasignificantpercentageofthesepatients.More-
over, CPAP provided protection against having a riser pattern
at the end of the study compared to the control group. This is
an important point because patients with a riser blood pres-
sure pattern exhibit the highest cardiovascular risk.33,34
Some authors have reported that the effect of CPAP treat-
mentonbloodpressure levelsdependson thenumberofhours
of CPAPuse.28 Our study corroborates this finding,with a sig-
nificant correlation between the hours of CPAP use (espe-
cially in patientswith at least 4hours of useper night) and the
decrease in blood pressure levels. Adherence to CPAP treat-
ment was good in the present study, with more than 70% of
patients using CPAP for 4 or more hours per night, an adher-
ence rate similar to that reported in other large studies of pa-
tients with OSA.35
In our study we chose not to use sham CPAP as a placebo
because studieshave shown that excessive air leaking and low
airpressure (necessary todeliver avery low,noneffectivepres-
sure of 2-3 cm H2O), along with the persistence of symptoms
such as snoring or breathing pauses, makes the patients real-
ize that they arenot receiving an effective treatment.23,36 Sev-
eral studies have reported lower CPAP compliancewith sham
CPAP compared to optimal CPAP, suggesting that this device
fails to function as a true placebo.37,38
The major strength of our study is its randomized multi-
center clinical trial designwith a sample size sufficient to en-
able both an ITT andper-protocol analyses. In addition, resis-
tanthypertensionwasestablishedbymeansof 24-hourABPM,
as recently recommended to provide more accurate esti-
mates of bloodpressure in thesepatients.19Nevertheless, this
studyhasseveral limitations.First, respiratorypolygraphydoes
not permit any quantification of the duration of sleep. This is
unlikely toaffectourconclusionsbecausepatients inour study
had an average AHI of more than 40 events per hour (severe
OSA). Indeed, thecorrelationbetween theAHIcalculated from
respiratory polygraphy and the AHI derived from full poly-
somnography isveryhigh in severeOSA.39 Second, in this trial,
we opted for titration of a fixed pressure bymeans of an auto
CPAPdeviceandthenusedthis targetpressure for the3months
of the study.This approachwasusedbecause fixedCPAPpres-
sure is the most common method applied to OSA patients in
Spain.Moreover, a recent study failed todemonstrate anydif-
ferences in bloodpressure levelswhenusing fixedCPAPpres-
sure in comparison to auto CPAP devices.40
Conclusions
Among patients with OSA and resistant hypertension, CPAP
treatment for 12weeks, compared to control, resulted in a de-
crease in 24-hour mean and diastolic blood pressure and an
improvement in the nocturnal blood pressure pattern. Fur-
ther research is warranted to assess longer-term health out-
comes.
Figure 2. Correlation Between Changes in 24-HourMean, Systolic, and Diastolic Blood Pressure and Number of Hours of Continuous Positive Airway
Pressure Use
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Correlation between continuous positive airway pressure (CPAP) use and change in blood pressure in the patients of the CPAP group who finished the follow-up.
Table 4. Effect of Continuous Positive Airway Pressure Treatment on Prevalence of Blood Pressure Patterns
No. (%)
OR (95% CI)a P Value
CPAP Group
(n = 98)
Control Group
(n = 96)
Baseline Follow-up Baseline Follow-up
Prevalence dipper
pattern
25 (25.5) 35 (35.9) 25 (26.0) 21 (21.6) 2.4 (1.2-5.1) .02
Prevalence riser
pattern
27 (27.6) 20 (20.5) 34 (35.4) 35 (36.8) 0.45 (0.23-0.91) .03
Abbreviations: CPAP, continuous positive airway pressure; OR, odds ratio.
a Adjusted for baseline status. Control group data were reference values. Odds
ratio (95% CI) of dipper or riser pattern 12 weeks after CPAP treatment relative
to the control group.
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